A dose-response trial of nebivolol in essential hypertension

Journal of Human Hypertension

Volumn 11, Issue 2, 1997, Pages 139-144

  Van Nueten, L ^a   Dupont, A G ^a   Vertommen, C ^a   Goyvaerts, H ^a   Robertson, J I S ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Black patients; Hypertension therapeutic trials; Nitric oxide; Side effects; Vasodilation; blockers

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NEBIVOLOL; NITRIC OXIDE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; HEADACHE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEGRO; ORAL DRUG ADMINISTRATION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TREATMENT OUTCOME; VASODILATATION; VERTIGO;

EID: 0030977599     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000392     Document Type: Article

References (27)

1. 1-adrenergic antagonist. J Cardiovasc Pharmacol 1988; 11: 552-562.
2. Janssens WJ et al. Nebivolol is devoid of intrinsic sympathomimetic activity. Eur J Pharmacol 1989; 159: 89-95.
3. Fitzgerald JD (ed). First nebivolol investigators' meeting. Drug Investigation 1991; 3 (Suppl 1): 1-203.
4. Lacourcière Y et al. Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24 hour ambulatory pressure and plasma lipoproteins. J Clin Pharmacol 1992; 32: 660-666.
5. Van Bortel LM et al. Nebivolol in hypertension: a double-blind placebo-controlled multicentre study assessing its anithypertensive efficacy and impact on quality of life. J Cardiovasc Pharmacol 1993; 21: 856-862.
6. Lacourcière Y et al. Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination. A randomized, double-blind, placebo-controlled, factorial-design trial. Am J Hypertens 1994; 7: 137-145.
7. Lacourcière Y et al. A double-blind cross-over comparison of nebivolol and lisinopril in the treatment of ambulatory hypertension. Am J Ther 1994; 1: 74-80.
8. Gao Y et al. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol 1991; 17: 964-969.
9. Cockroft JR et al. Nebivolol vasodilates human forearm vasculature: evidence for an 1-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067-1071.
10. Bowman AJ, Chen CPL, Ford GA. Nitric oxidemediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994; 38: 199-204.
11. Van Rooy P, Van Nueten L, De Crée J. Nebivolol: blood pressure reduction in relation to β-blockade in healthy volunteers. Drug Investigation 1991; 3 (Suppl 1): 174-175.
12. Stoleru L et al. Effects of D-nebivolol and L-nebivolol on the left ventricular systolic and diastolic function: comparison with D-L nebivolol and atenolol. J Cardiovasc Pharmacol 1993; 22: 183-190.
13. Goldstein M et al. Administration of nebivolol after coronary artery bypass graft in patients with altered left ventricular function. J Cardiovasc Pharmacol 1993; 22: 253-258.
14. Rousseau MF et al. Medium term effects on beta-blockade on left ventricular mechanics: a double-blind, placebo controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction. J Card Fail 1996; 2: 15-23.
15. Van Merode T et al. Verapamil and nebivolol improve carotid artery distensibility in hypertensive patients. J Hypertens 1989; 7 (Suppl 6): S262-S263.
16. Kodell RL, Chen JJ. Characterization of dose-response relationships inferred by statistically significant trend tests. Biometrics 1991; 47: 139-146.
17. Rose M, McMahon F. Some problems with anithypertensive drug studies in the context of the new guidelines. Am J Hypertens 1990; 3: 151-155.
18. Cruickshank JM, Prichard BNC. Betablockers in Clinical Practice. Churchill Livingston, Edinburgh, London, Melbourne, New York, 1987.
19. Lipicky RJ. Trough:peak ratio: the rationale behind the United States Food and Drug Administration recommendations. J Hypertens 1994; 12 (Suppl 8): 17-19.
20. Wing LMH. Trough:peak ratio of the blood pressure response to beta-blockes. J Hypertens 1994; 12 (Suppl. 8): 85-90.
21. Van Peer A et al. Clinical pharmacokinetics of nebivolol: a review. Drug Investigation 1991; 3 (Suppl 1): 25-30.
22. Fifth Report of the Joint National Committee on Detection, Evaluation, and treatment of High Blood pressure (JNC-V). Arch Int Med 1993; 153: 154-182.
23. Barraclough M et al. Control of moderately raised blood pressure: report of a co-operative randomized controlled trial. Br Med J 1973; 3: 434-436.
24. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J 1985; 291: 97-104.
25. Medical Research Council Working Party. MRC trial of treatment of hypertension in older adults: principal results. Br Med J 1992; 304: 405-412.
26. Moncada S, Higgs A. The L-arginine - nitric oxide pathway. N Eng J Med 1993; 27: 2002-2012.
27. Moncada S. Nitric oxide. J Hypertens 1994; 12 (Suppl 10): 35-39.